Escalon Medical (ESMC) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Escalon Medical Corp   (ESMC)

Escalon Medical 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Escalon Medical in the third quarter 2026?
Escalon Medical Corp achieved a return on average equity (ROE) of 83.4 % in its third quarter 2026, this is above ESMC's average return on equity of -24.63%.
Escalon Medical Corp shareholder's equity over the 12 months ending in its third quarter 2026 are valued at $2 million

ROE has advanced compared to 11.24% in the second quarter 2025, due to net income growth.

Within the Medical Equipment & Supplies industry 78 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2025 from 2648 to 2680.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2026)
III. Quarter		 (Dec 31 2025)
II. Quarter		 (Sep 30 2025)
I. Quarter		 (Jun 30 2025)
IV. Quarter		 (Mar 31 2025)
III. Quarter
Y / Y Equity Change - 80.68 % 5.83 % -5.74 % -
Y / Y Net Income Change - - - 329.37 % -
Net Income (TTM) in Millions 2 0 0 0 0
Return On Equity (TTM) 83.4 % 11.24 % 5.37 % 20.94 % -2.05 %
ESMC's Total Ranking # 2680 # 2648 # # #
Equity (TTM) in Millions 0 4 2 2 2
Seq. Equity Change - 116.51 % 14.31 % -12.52 % -16.55 %
Seq. Net Income Change 2046.3 % - - - -

Back to ESMC Management Effectiveness >> ESMC's 5 Years Annual ROE >> Compare ESMC ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 79
Sector # 249
Overall # 2680

Return On Equity Statistics
High Average Low
30.2 %
-24.63 %
-118.32 %
(Jun 30 2018)   (Dec 31 2013)





ESMC Annual Return On Equity (Jun 30 2025)
2025		 (Jun 30 2024)
2024		 (Jun 30 2023)
2023		 (Jun 30 2022)
2022		 (Jun 30 2021)
2021
Total Equity in Millions 2 2 2 1 1
Y / Y Equity Change 5.83 % -6.47 % 30.91 % 1.24 % -3.44 %
Net Income in Millions 0 0 0 0 0
Y / Y Net Income Change - - 1408.84 % - -
Return On Equity 4.16 % -6.92 % 14.12 % 1.22 % -3.56 %

Back to ESMC Management Effectiveness >> ESMC's 5 Years Annual ROE >> Compare ESMC ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 4.16 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ESMC's' Return on Equity at Yahoo Finance
ESMC's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ESMC's Competitors
Subscribers only: Roe for Escalon Medical 's Suppliers
Subscribers only: Return On Equity for ESMC's Customers




Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector ROE
Emmis Acquisition Corp   224.85 %
Interpace Biosciences Inc   215.31 %
Coherus Oncology inc   214.57 %
Oncotelic Therapeutics Inc   183.27 %
Arbutus Biopharma Corp  169.38 %
Rigel Pharmaceuticals Inc  147.03 %
Fortress Biotech Inc   140.48 %
Halozyme Therapeutics Inc   126.27 %
Petros Pharmaceuticals inc   124.23 %
Advanced Biomed Inc.  121.71 %
Medpace Holdings Inc   120.89 %
Capforce Inc   110.42 %
Eli Lilly And Company  101.17 %
Qhslab Inc   91.63 %
Amgen Inc   89.41 %
Exelixis Inc   88.60 %
Entera Bio Ltd   87.97 %
Tg Therapeutics Inc   87.36 %
Alnylam Pharmaceuticals Inc   86.11 %
Zevra Therapeutics Inc   81.34 %
Pulmatrix Inc   78.57 %
Earth Science Tech Inc   71.44 %
Idexx Laboratories Inc  70.87 %
Elite Pharmaceuticals Inc   68.60 %
Escalon Medical Corp   66.85 %
3m Company  65.54 %
Aurinia Pharmaceuticals Inc   64.48 %
Lifemd Inc   63.70 %
Zoetis Inc   61.63 %
Vaxart Inc   61.43 %

Date modified: 2026-09-12T06:11:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.